215 related articles for article (PubMed ID: 15032718)
1. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
Russo P; Loprevite M; Cesario A; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
4. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
6. [Development of farsenyl transferase inhibitors as anticancer agents].
Cestac P; Doisneau-Sixou S; Favre G
Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
[TBL] [Abstract][Full Text] [Related]
7. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability.
Falugi C; Trombino S; Granone P; Margaritora S; Russo P
Curr Cancer Drug Targets; 2003 Apr; 3(2):109-18. PubMed ID: 12678714
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
Morgan MA; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
[TBL] [Abstract][Full Text] [Related]
9. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
Basso AD; Kirschmeier P; Bishop WR
J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
[TBL] [Abstract][Full Text] [Related]
10. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
11. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
12. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
14. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Crul M; de Klerk GJ; Beijnen JH; Schellens JH
Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
16. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
17. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors.
Sebti SM; Adjei AA
Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
Sebti SM; Hamilton AD
Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
[TBL] [Abstract][Full Text] [Related]
20. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
